tradingkey.logo

Avalon Globocare Corp

ALBT
0.635USD
+0.031+5.22%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
2.60MMarktkapitalisierung
VerlustKGV TTM

Avalon Globocare Corp

0.635
+0.031+5.22%

mehr Informationen über Avalon Globocare Corp Unternehmen

Avalon GloboCare Corp. is a commercial-stage company engaged in developing and delivering precision diagnostic consumer products and the advancement of intellectual property in cellular therapy. The Company operates in two reportable business segments: the real property operating segment and the laboratory testing services segment. Its laboratory services offer a test menu that satisfies the clients' testing needs, from general bloodwork to anatomic pathology, urine toxicology, pharmacogenomics (PGx) testing and more, and it is a one-stop-shop for clinical testing. The Company is currently marketing the KetoAir breathalyzer device and plans to develop additional diagnostic uses of the breathalyzer technology. The KetoAir breathalyzer is a handheld device that allows the user to detect acetone levels in exhaled breath. The acetone level is in concentration units part-per-million (ppm) such that the user knows the real-time ketosis status.

Avalon Globocare Corp Informationen

BörsenkürzelALBT
Name des UnternehmensAvalon Globocare Corp
IPO-datumFeb 22, 2016
CEOJin (David)
Anzahl der mitarbeiter5
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 22
Addresse4400 Route 9
StadtFREEHOLD
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl07728
Telefon17327804400
Websitehttps://www.avalon-globocare.com/
BörsenkürzelALBT
IPO-datumFeb 22, 2016
CEOJin (David)

Führungskräfte von Avalon Globocare Corp

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Wenzhao (Daniel) Lu
Mr. Wenzhao (Daniel) Lu
Chairman of the Board of Directors
Chairman of the Board of Directors
238.93K
--
Dr. David Jin, M.D., Ph.D.
Dr. David Jin, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
103.00K
--
Ms. Meng Li
Ms. Meng Li
Chief Operating Officer, Secretary
Chief Operating Officer, Secretary
34.33K
--
Mr. Steven Andrew Sanders, J.D.
Mr. Steven Andrew Sanders, J.D.
Independent Director
Independent Director
--
--
Mr. Wilbert J. (Billy) Tauzin, II
Mr. Wilbert J. (Billy) Tauzin, II
Director
Director
--
--
Mr. William B. Stilley, III
Mr. William B. Stilley, III
Independent Director
Independent Director
--
--
Dr. The Hon. Tevi Troy, Ph.D.
Dr. The Hon. Tevi Troy, Ph.D.
Independent Director
Independent Director
--
--
Ms. Luisa Ingargiola
Ms. Luisa Ingargiola
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Lourdes Felix
Ms. Lourdes Felix
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Wenzhao (Daniel) Lu
Mr. Wenzhao (Daniel) Lu
Chairman of the Board of Directors
Chairman of the Board of Directors
238.93K
--
Dr. David Jin, M.D., Ph.D.
Dr. David Jin, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
103.00K
--
Ms. Meng Li
Ms. Meng Li
Chief Operating Officer, Secretary
Chief Operating Officer, Secretary
34.33K
--
Mr. Steven Andrew Sanders, J.D.
Mr. Steven Andrew Sanders, J.D.
Independent Director
Independent Director
--
--
Mr. Wilbert J. (Billy) Tauzin, II
Mr. Wilbert J. (Billy) Tauzin, II
Director
Director
--
--
Mr. William B. Stilley, III
Mr. William B. Stilley, III
Independent Director
Independent Director
--
--

Umsatzaufteilung

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Sun, Jan 18
Aktualisiert: Sun, Jan 18
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Lu (Wenzhao)
5.62%
Jin (David)
2.42%
Li (Meng)
0.81%
The Vanguard Group, Inc.
0.60%
UBS Financial Services, Inc.
0.57%
Andere
89.98%
Aktionäre
Aktionäre
Anteil
Lu (Wenzhao)
5.62%
Jin (David)
2.42%
Li (Meng)
0.81%
The Vanguard Group, Inc.
0.60%
UBS Financial Services, Inc.
0.57%
Andere
89.98%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
8.87%
Investment Advisor
1.61%
Investment Advisor/Hedge Fund
0.52%
Hedge Fund
0.01%
Andere
88.99%

Institutionelle Beteiligung

Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
29
48.23K
1.25%
--
2025Q3
31
48.23K
1.39%
+17.57K
2025Q2
33
19.75K
2.15%
+2.84K
2025Q1
33
16.91K
2.05%
-16.99K
2024Q4
35
16.66K
2.06%
-67.00
2024Q3
33
16.73K
1.75%
-236.00
2024Q2
33
16.96K
1.41%
+10.31K
2024Q1
31
6.65K
1.69%
-5.84K
2023Q4
32
10.45K
1.58%
+1.42K
2023Q3
39
9.06K
1.97%
+456.00
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Lu (Wenzhao)
238.93K
5.62%
--
--
Oct 31, 2025
Jin (David)
103.00K
2.42%
--
--
Oct 31, 2025
Li (Meng)
34.33K
0.81%
--
--
Oct 31, 2025
The Vanguard Group, Inc.
25.38K
0.6%
+23.80K
+1505.50%
Sep 30, 2025
UBS Financial Services, Inc.
42.00
0%
-4.16K
-99.00%
Sep 30, 2025
Geode Capital Management, L.L.C.
22.07K
0.52%
+12.74K
+136.48%
Sep 30, 2025
Tauzin (Wilbert J II)
1.04K
0.02%
--
--
Oct 31, 2025
Tower Research Capital LLC
453.00
0.01%
+212.00
+87.97%
Sep 30, 2025
Citi Investment Research (US)
131.00
0%
-820.00
-86.23%
Sep 30, 2025
Mehr Anzeigen

Verbundene ETFs

Name
Anteil
Keine Daten

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Oct 24, 2024
Merger
15→1
Oct 24, 2024
Merger
15→1
Oct 24, 2024
Merger
15→1
Oct 24, 2024
Merger
15→1
Jan 04, 2023
Merger
10→1
Jan 04, 2023
Merger
10→1
Datum
Ex-Dividendentag
Art
Verhältnis
Oct 24, 2024
Merger
15→1
Oct 24, 2024
Merger
15→1
Oct 24, 2024
Merger
15→1
Oct 24, 2024
Merger
15→1
Jan 04, 2023
Merger
10→1
Jan 04, 2023
Merger
10→1
Jan 04, 2023
Merger
10→1
Jan 04, 2023
Merger
10→1
KeyAI